4.5 Article

Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients

Related references

Note: Only part of the references are listed.
Article Oncology

The Epidemiology of Herpes Zoster in Patients with Newly Diagnosed Cancer

Laurel A. Habel et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)

Article Medicine, General & Internal

Herpes Zoster

Jeffrey I. Cohen

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Oncology

Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib

Ulrike Heider et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)

Letter Oncology

Does Bortezomib Induce De Facto Varicella Zoster Virus Reactivation in Patients With Multiple Myeloma?

Constantin A. Dasanu et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Article Oncology

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

Asher Chanan-Khan et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Article Medicine, General & Internal

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Meletios Dimopoulos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Medicine, General & Internal

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

Donna M. Weber et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)